Measuring the Outcomes of International Oncology Regulatory Collaboration in Canada from 2019 to 2025: Project Orbis

Jonathan Zaslavsky, David C Sealey · 2026

Read Measuring the Outcomes of International Oncology Regulatory Collaboration in Canada from 2019 to 2025: Project Orbis by Jonathan Zaslavsky, David C Sealey (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13631845.txt.

Description

Jonathan Zaslavsky and David C Sealey measure, in a 2026 study, what an international drug review program has meant for Canada. Project Orbis, launched by the United States drug agency in 2019, lets regulators in several countries review cancer drugs in step with each other. The authors used public data on drug approval requests to gauge the program's effect from 2019 to 2025.

In that span, Health Canada approved 97 cancer requests under Orbis and 161 outside it. Orbis requests showed shorter gaps between the United States and Canadian filings and decisions, and a shorter median time to a decision. Times met Health Canada's own performance standards. The authors note that Canada has been a very active partner, and they call for study of whether the program speeds the full path to patient access.

Catalog record

CREATORJonathan Zaslavsky, David C Sealey
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE21 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13631845

Browse the full library · About the Tower of Babel